Biotech Sector Continues To Grow

Mid-sized to small specialty pharmaceutical companies are experiencing drastic shortages in funding. The global financial crisis means there is a low appetite for risk and less likelihood of investment in development-stage companies, which include most biotechnology firms. BMI notes that this was particularly evident in the capital investment figures for the Swiss biotech industry. In 2009, the industry received investment of CHF370mn (US$333mn), with 20 private companies accounting for 86% of the investment. While this is an improvement from the CHF228mn (US$205mn) invested in 2008, it is nowhere near the CHF885mn (US$797mn) investment in

To read the full article, please choose one of the following options: